CDK Inhibitors

CDK1

CDK2

CDK3

CDK4

CDK5

CDK6

CDK7

CDK8

CDK9

CDK11

CDK12

CDK13

CDK14

CDK16

CDK19

CDC

CLK

Pho85

CDK10

CDK15

CDK17

CDK18

CDK20

PITSLRE

CDK Degraders, Inhibitors, Agonists, Antagonists & Activators

Product Name	CDK1	CDK2	CDK3	CDK4	CDK5	CDK6	CDK7	CDK8	CDK9	CDK11	CDK12	CDK13	CDK14	CDK16	CDK19	CDC	CLK	Pho85	CDK10	CDK15	CDK17	CDK18	CDK20	PITSLRE	Purity
Palbociclib				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM																			99.94%
Abemaciclib	CDK1/cyclinB1, IC₅₀: 1627 nM	CDK2/cyclinE, IC₅₀: 504 nM		Cdk4/cyclin D1, IC₅₀: 2 nM	CDK5/p35, IC₅₀: 287 nM Cdk5/p25, IC₅₀: 355 nM	CDK6/cyclinD1, IC₅₀: 10 nM	CDK7/Mat1/cyclinH1, IC₅₀: 3910 nM		CDK9/cyclinT1, IC₅₀: 57 nM																99.97%
Ro-3306	CDK1, Ki: 20 nM CDK1/cyclinB1, Ki: 35 nM CDK1/cyclin A, Ki: 110 nM	CDK2/cyclinE, Ki: 340 nM																							99.83%
Ribociclib				CDK4, IC₅₀: 10 nM		CDK6, IC₅₀: 39 nM																			99.94%
KI-CDK9d-32									CDK9, DC₅₀: 0.89 nM																98.99%
CDK4-IN-3				CDK4, IC₅₀: 25 nM																					98.07%
CGP-74514	CDK1/cyclinB1, IC₅₀: 25 nM
Dinaciclib	CDK1, IC₅₀: 3 nM	CDK2, IC₅₀: 1 nM			CDK5, IC₅₀: 1 nM				CDK9, IC₅₀: 4 nM																99.80%
Flavopiridol	CDK1/Cyc B1, IC₅₀: 30 nM	CDK2/Cyc E, IC₅₀: 170 nM		CDK4/Cyc D1, IC₅₀: 100 nM																					99.73%
GSK3326595				CDK4		CDK6																			99.83%
(R)-Roscovitine	cdc2/cyclin B, IC₅₀: 0.65 μM	cdk2/cyclin A, IC₅₀: 0.7 μM Cdk2/cyclin E2, IC₅₀: 0.7 μM			CDK5/p35, IC₅₀: 0.16 μM																				99.53%
Palbociclib hydrochloride				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM																			99.96%
THZ1							CDK7, IC₅₀: 3.2 nM																		99.84%
Palbociclib monohydrochloride				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM																			99.98%
AZD4573									CDK9, IC₅₀: 4 nM																99.98%
Palbociclib isethionate				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM																			99.95%
THZ531							CDK7, IC₅₀: 8.5 μM		CDK9, IC₅₀: 10.5 μM		CDK12, IC₅₀: 158 nM	CDK13, IC₅₀: 69 nM													99.86%
Abemaciclib methanesulfonate	CDK1/cyclinB1, IC₅₀: 1627 nM	CDK2/cyclinE, IC₅₀: 504 nM		Cdk4/cyclin D1, IC₅₀: 2 nM	Cdk5/p25, IC₅₀: 355 nM CDK5/p35, IC₅₀: 287 nM	CDK6/cyclinD1, IC₅₀: 10 nM	CDK7/Mat1/cyclinH1, IC₅₀: 3910 nM		CDK9/cyclinT1, IC₅₀: 57 nM																99.95%
Tagtociclib hydrate		CDK2/cyclin E1, Ki: 1.16 nM																							99.73%
Wogonin								CDK8																	99.92%
Kenpaullone	Cdk1/cyclin B, IC₅₀: 0.4 μM	cdk2/cyclin A, IC₅₀: 0.68 μM CDK2/cyclinE, IC₅₀: 7.5 μM			Cdk5/p25, IC₅₀: 0.85 μM																				98.20%
SR-4835											CDK12, IC₅₀: 99 nM CDK12, Kd: 98 nM	CDK13, Kd: 4.9 nM													99.73%
SNS-032	CDK1, IC₅₀: 480 nM	CDK2, IC₅₀: 38 nM		CDK4, IC₅₀: 925 nM			CDK7, IC₅₀: 62 nM		CDK9, IC₅₀: 4 nM																99.91%
GSK 3 Inhibitor IX	Cdk1/cyclin B, IC₅₀: 320 nM	cdk2/cyclin A, IC₅₀: 300 nM		Cdk4/cyclin D1, IC₅₀: 10 μM	CDK5/p35, IC₅₀: 80 nM																				99.73%
SY-5609		CDK2, Ki: 2600 nM					CDK7, Kd: 0.065 nM		CDK9, Ki: 960 nM		CDK12, Ki: 870 nM														99.33%
hSMG-1 inhibitor 11j	CDK1, IC₅₀: 32 μM	CDK2, IC₅₀: 7.1 μM																							99.82%
Toyocamycin		CDK2/cyclinA, IC₅₀: 0.67 μM		Cdk4/cyclin D3, IC₅₀: 15 μM		cdk6/cyclin D3, IC₅₀: >10 μM	CDK7/Mat1/cyclinH1, IC₅₀: 2.8 μM		CDK9/cyclinT1, IC₅₀: 79 nM																99.27%
NVP-2									CDK9, IC₅₀: 0.5 nM																99.60%
OTS964 hydrochloride										CDK11B, Kd: 40 nM															99.74%
Samuraciclib hydrochloride	CDK1, IC₅₀: 1.8 μM	CDK2, IC₅₀: 578 nM		CDK4, IC₅₀: 49 μM	CDK5, IC₅₀: 9.4 μM	CDK6, IC₅₀: 34 μM	CDK7, IC₅₀: 41 nM		CDK9, IC₅₀: 1.2 μM																99.98%
Amantadine		CDK2																							99.90%
Simurosertib																Cdc7, IC₅₀: <0.3 nM									99.94%
BI-1347								CDK8, IC₅₀: 1.1 nM																	99.84%
CPS2		CDK2, IC₅₀: 24 nM																							99.33%
AT7519	Cdk1/cyclin B, IC₅₀: 210 nM	cdk2/cyclin A, IC₅₀: 47 nM		Cdk4/cyclin D1, IC₅₀: 100 nM	CDK5/p35, IC₅₀: 13 nM	cdk6/cyclin D3, IC₅₀: 170 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM		CDK9/Cyclin T, IC₅₀: 10 nM																99.69%
JNJ-7706621	Cdk1/cyclin B, IC₅₀: 9 nM	CDK2/cyclinE, IC₅₀: 3 nM cdk2/cyclin A, IC₅₀: 4 nM	CDK3/Cyclin E, IC₅₀: 58 nM	Cdk4/cyclin D1, IC₅₀: 253 nM		CDK6/cyclinD1, IC₅₀: 175 nM																			99.39%
YKL-5-124		CDK2, IC₅₀: 1300 nM					CDK7, IC₅₀: 53.5 nM CDK7/Mat1/CycH, IC₅₀: 9.7 nM		CDK9, IC₅₀: 3020 nM																99.53%
AZD-5438	cdk1-cyclin B1, IC₅₀: 16 nM	cdk2-cyclin E, IC₅₀: 6 nM cdk2-cyclin A, IC₅₀: 45 nM		cdk4-cyclin D1, IC₅₀: 449 nM	cdk5-p25, IC₅₀: 14 nM	cdk6-cyclin D3, IC₅₀: 21 nM	cdk7-cyclin H, IC₅₀: 821 nM		cdk9-cyclin T, IC₅₀: 20 nM																99.91%
AS2863619								CDK8, IC₅₀: 0.61 nM							CDK19, IC₅₀: 4.28 nM										99.94%
Enitociclib									CDK9/CycT1, IC₅₀: 3 nM																99.89%
TG003																	CLK1, IC₅₀: 20 nM CLK2, IC₅₀: 200 nM CLK4, IC₅₀: 15 nM								99.57%
Ribociclib hydrochloride				CDK4, IC₅₀: 10 nM		CDK6, IC₅₀: 39 nM																			99.95%
MBQ-167																Cdc42, IC₅₀: 78 nM									99.64%
BSJ-4-116											CDK12, IC₅₀: 6 nM														99.87%
KB-0742 dihydrochloride	CDK1/cyclin A, IC₅₀: 2980 nM	cdk2/cyclin A, IC₅₀: 397 nM	CDK3/Cyclin E, IC₅₀: 1420 nM	CDK4/cyclin D, IC₅₀: 3130 nM	Cdk5/p25, IC₅₀: 1820 nM	CDK6/cyclinD1, IC₅₀: 3950 nM	CDK7/cyclin H, IC₅₀: 1510 nM	CDK8/cyclin C, IC₅₀: >10000 nM	CDK9/cyclinT1, IC₅₀: 6 nM																99.24%
SLK/STK10-IN-1																	CLK2, IC₅₀: 39 nM								99.78%
Flavopiridol Hydrochloride	CDK1/Cyc B1, IC₅₀: 30 nM	CDK2/Cyc E, IC₅₀: 170 nM		CDK4/Cyc D1, IC₅₀: 100 nM																					99.73%
CVT-313	Cdk1/cyclin B, IC₅₀: 4.2 μM	cdk2/cyclin A, IC₅₀: 0.5 μM		Cdk4/cyclin D1, IC₅₀: 215 μM																					99.90%
Fadraciclib		CDK2							CDK9																99.78%
Ribociclib succinate				CDK4, IC₅₀: 10 nM		CDK6, IC₅₀: 39 nM																			99.93%
hSMG-1 inhibitor 11e	CDK1, IC₅₀: 32 μM	CDK2, IC₅₀: 7.1 μM																							99.94%
CLK-IN-T3																	CLK1, IC₅₀: 0.67 nM CLK2, IC₅₀: 15 nM CLK3, IC₅₀: 110 nM								98.63%
BTX-A51							CDK7, Kd: 1.3 nM		CDK9, Kd: 4 nM																98.58%
(R)-CR8	Cdk1/cyclin B, IC₅₀: 0.09 μM	cdk2/cyclin A, IC₅₀: 0.072 μM CDK2/cyclinE, IC₅₀: 0.041 μM			Cdk5/p25, IC₅₀: 0.11 μM		CDK7/cyclin H, IC₅₀: 1.1 μM		CDK9/Cyclin T, IC₅₀: 0.18 μM																99.61%
Romaciclib monohydrochloride								CDK8/CycC, IC₅₀: 4.4 nM	CDK9/cycT, IC₅₀: 1070 nM						CDK19/CycC, IC₅₀: 10.4 nM										99.29%
Ebvaciclib		CDK2, Ki: 0.09 nM		CDK4, Ki: 0.13 nM		CDK6, Ki: 0.16 nM																			99.98%
Nimbolide				CDK4		CDK6																			99.79%
NU6300		CDK2																							98.44%
Mevociclib							CDK7																		99.27%
Tambiciclib	Cdk1/cyclin B, IC₅₀: 5410 nM	cdk2/cyclin A, IC₅₀: 6850 nM	CDK3/cyclin E1, IC₅₀: >10000 nM		Cdk5/p25, IC₅₀: 6950 nM		CDK7/Cyclin H/MNAT1, IC₅₀: 3700 nM	CDK8/cyclin C, IC₅₀: >10000 nM	CDK9, IC₅₀: 1 nM	CDK11, IC₅₀: >10000 nM			CDK14/Cyclin Y, IC₅₀: 2710 nM	CDK16/Cyclin Y, IC₅₀: 195 nM											99.21%
NG 52	cdc2-cyclin B, IC₅₀: 0.34 μM				Pho85p, IC₅₀: 2 nM																				99.88%
Senexin B								CDK8, Kd: 140 nM							CDK19, Kd: 80 nM										99.09%
CGP60474	CDK1-Cyclin B, IC₅₀: 26 nM	CDK2/cyclinE, IC₅₀: 3 nM cdk2/cyclin A, IC₅₀: 4 nM		CDK4/cyclin D, IC₅₀: 216 nM	Cdk5/p25, IC₅₀: 10 nM		CDK7/cyclin H, IC₅₀: 200 nM		CDK9/cycT, IC₅₀: 13 nM																98.90%
PF 477736	CDK1, Ki: 9.9 μM																								99.04%
MSC2530818								CDK8, IC₅₀: 2.6 nM																	99.62%
FMF-04-159-2		CDK2, IC₅₀: 256 nM (in NanoBRET assay)											CDK14/Cyclin Y, IC₅₀: 39.6 nM (in NanoBRET assay)												99.64%
PROTAC CDK2/9 Degrader-1		CDK2, DC₅₀: 62 nM							CDK9, DC₅₀: 33 nM																99.85%
THZ1 Hydrochloride							CDK7, IC₅₀: 3.2 nM																		99.06%
TL12-186		cdk2/cyclin A, IC₅₀: 73 nM							CDK9/cyclinT1, IC₅₀: 55 nM																99.63%
BSJ-03-204				CDK4/D1, IC₅₀: 26.9 nM		CDK6/D1, IC₅₀: 10.4 nM																			99.76%
BSJ-04-132				CDK4/D1, IC₅₀: 50.6 nM		CDK6/D1, IC₅₀: 30 nM																			99.07%
AUZ 454		CDK2(C118L/A144C), Kd: 9.7 nM CDK2(A144C), Kd: 15.4 nM CDK2(C118L), Kd: 18.6 nM CDK2(WT), Kd: 50 nM CDK2(C118L/A144C-Cyclin B), Kd: 134.1 nM																							99.15%
Senexin A								CDK8, Kd: 0.83 μM CDK8, IC₅₀: 280 nM							CDK19, Kd: 0.31 μM										99.79%
XL413 monohydrochloride																Cdc7, IC₅₀: 3.4 nM									99.65%
XY028-140				CDK4		CDK6																			98.52%
(E/Z)-Zotiraciclib		CDK2, IC₅₀: 13 nM																							99.96%
Purvalanol A	cdc2-cyclin B, IC₅₀: 4 nM	cdk2-cyclin E, IC₅₀: 35 nM cdk2-cyclin A, IC₅₀: 70 nM		cdk4-cyclin D1, IC₅₀: 850 nM	cdk5-p35, IC₅₀: 75 nM																				98.61%
Cucurbitacin E	cyclin B1/CDC2																								99.92%
T025																	CLK1, Kd: 4.8 nM CLK2, Kd: 0.096 nM CLK3, Kd: 6.5 nM CLK4, Kd: 0.61 nM								99.64%
BSJ-03-123						CDK6																			99.19%
CCT-251921								CDK8, IC₅₀: 2.3 nM							CDK19, IC₅₀: 2.6 nM										99.12%
Amantadine hydrochloride		CDK2																							98.0%
Rogocekib																	CLK2, IC₅₀: 1.4 nM								98.15%
LDC000067	cdk1-cyclin B1, IC₅₀: 5513 nM	cdk2-cyclin A, IC₅₀: 2441 nM		cdk4-cyclin D1, IC₅₀: 9242 nM					CDK9- Cyclin T1, IC₅₀: 44 nM																99.00%
BMS-265246	CDK1/cycB, IC₅₀: 6 nM	CDK2/Cyc E, IC₅₀: 9 nM		CDK4/cycD, IC₅₀: 230 nM																					99.59%
Milciclib	cyclin B/CDK1, IC₅₀: 398 nM	cyclin A/CDK2, IC₅₀: 45 nM cyclin E/CDK2, IC₅₀: 363 nM		cyclin D1/CDK4, IC₅₀: 160 nM			cyclin H/CDK7, IC₅₀: 150 nM																		99.90%
Sinigrin				CDK4		CDK6																			99.97%
PHA-767491 hydrochloride	CDK1, IC₅₀: 250 nM	CDK2, IC₅₀: 240 nM			CDK5, IC₅₀: 460 nM				CDK9, IC₅₀: 34 nM																99.49%
Roniciclib	Cdk1/cyclin B, IC₅₀: 7 nM	CDK2/cyclinE, IC₅₀: 9 nM		CDK4/cyclin D, IC₅₀: 11 nM			CDK7/Cyclin H/MAT1, IC₅₀: 25 nM		CDK9/cyclinT1, IC₅₀: 5 nM																98.09%
R547	Cdk1/cyclin B, Ki: 2 nM Cdk1/cyclin B, IC₅₀: 0.2 nM	CDK2/cyclinE, Ki: 3 nM cdk2/cyclin A, IC₅₀: 0.1 nM CDK2/cyclinE, IC₅₀: 0.4 nM	CDK3/Cyclin E, IC₅₀: 0.8 nM	CDK4/cyclin D, Ki: 1 nM	CDK5/p35, IC₅₀: 0.1 nM	cdk6/cyclin D3, IC₅₀: 4 nM	CDK7/cyclin H, IC₅₀: 171 nM																		99.57%
SU9516	CDK1, IC₅₀: 40 nM	CDK2, IC₅₀: 22 nM		CDK4, IC₅₀: 200 nM																					99.85%
XL413																Cdc7, IC₅₀: 3.4 nM									99.76%
Atuveciclib	CDK1/CycB(h), IC₅₀: 1100 nM	CDK2/CycE(h), IC₅₀: 1000 nM	CDK3/CycE(h), IC₅₀: 890 nM		CDK5/p35(h), IC₅₀: 1600 nM				CDK9/CycT1, IC₅₀: 13 nM CDK9/CycT1(h), IC₅₀: 6 nM																99.75%
Dalpiciclib				CDK4, IC₅₀: 12.4 nM		CDK6, IC₅₀: 9.9 nM																			99.70%
XO44	CDK1	CDK2		CDK4																					99.38%
Alsterpaullone	Cdk1/cyclin B, IC₅₀: 35 nM	cdk2/cyclin A, IC₅₀: 15 nM CDK2/Cyc E, IC₅₀: 200 nM			CDK5/p35, IC₅₀: 40 nM																				99.85%
Thiabendazole	CCNE1	CDK2																							99.94%
Narazaciclib				Cdk4/cyclin D1, IC₅₀: 3.9 nM		CDK6/cyclinD1, IC₅₀: 9.82 nM																			98.66%
RGB-286638	cyclin B1-CDK1, IC₅₀: 2 nM	cyclin E-CDK2, IC₅₀: 3 nM	cyclin E-CDK3, IC₅₀: 5 nM	cyclin D1-CDK4, IC₅₀: 4 nM	p35-CDK5, IC₅₀: 5 nM	cyclin D3-CDK6, IC₅₀: 55 nM	cyclin H-CDK7, IC₅₀: 44 nM		T1-CDK9, IC₅₀: 1 nM																99.70%
THZ2	CDK1, IC₅₀: 96.9 nM	CDK2, IC₅₀: 222 nM			CDK5, IC₅₀: 134 nM		CDK7, IC₅₀: 13.9 nM	CDK8, IC₅₀: 6830 nM	CDK9, IC₅₀: 194 nM																99.03%
Trilaciclib hydrochloride				Cdk4/cyclin D1, IC₅₀: 1 nM		cdk6/cyclin D3, IC₅₀: 4 nM																			99.69%
TC11	CDK1																								99.55%
(R)-CR8 trihydrochloride	CDK1/cyclinB1, IC₅₀: 0.09 μM	cdk2/cyclin A, IC₅₀: 0.072 μM CDK2/cyclinE, IC₅₀: 0.041 μM			Cdk5/p25, IC₅₀: 0.11 μM		CDK7/cyclin H, IC₅₀: 1.1 μM		CDK9/Cyclin T, IC₅₀: 0.18 μM																99.37%
CDK2-IN-4	Cdk1/cyclin B, IC₅₀: 86 μM	cdk2/cyclin A, IC₅₀: 44 nM																							99.85%
Voruciclib	CDK1/cycB, Ki: 5.4 nM CDK1/cyc A, Ki: 9.1 nM			CDK4/Cyc D1, Ki: 3.96 nM		CDK6/cycD1, Ki: 2.92 nM			CDK9/cyc T2, Ki: 0.626 nM CDK9/CycT1, Ki: 1.68 nM																99.77%
Abemaciclib metabolite M2				CDK4, IC₅₀: 1.2 nM		CDK6, IC₅₀: 1.3 nM																			99.75%
Alisol B 23-acetate				CDK4		CDK6																			99.65%
Asnuciclib	CDK1, IC₅₀: 8.17 nM CDK1, Ki: 4 nM	CDK2, IC₅₀: 3.27 nM CDK2, Ki: 3 nM		CDK4, IC₅₀: 8.18 nM		CDK6, IC₅₀: 37.68 nM	CDK7, IC₅₀: 134.26 nM CDK7, Ki: 91 nM		CDK9, IC₅₀: 5.78 nM CDK9, Ki: 4 nM																99.76%
GFB-12811		CDK2/CycA, IC₅₀: 211 nM			Cdk5/p25, IC₅₀: 2.3 nM	CDK6, IC₅₀: 3197 nM	CDK7/Cyclin H/MAT1, IC₅₀: 718 nM		CDK9/CycT1, IC₅₀: 894 nM																98.04%
Romaciclib hydrochloride								CDK8/CycC, IC₅₀: 4.4 nM	CDK9/cycT, IC₅₀: 1070 nM						CDK19/CycC, IC₅₀: 10.4 nM										99.98%
(±)-Enitociclib									CDK9																99.87%
AZ5576									CDK9, : <5 nM																99.86%
CDK5 inhibitor 20-223		CDK2, IC₅₀: 6.0 nM			CDK5, IC₅₀: 8.8 nM																				99.62%
JH-XI-10-02								CDK8, IC₅₀: 159 nM																	99.73%
JSH-150	Cdk1/cyclin B, IC₅₀: 1.34 μM	cdk2/cyclin A, IC₅₀: 2.86 μM			Cdk5/p25, IC₅₀: 4.64 μM		CDK7/Cyclin H/MNAT1, IC₅₀: 1.72 μM		CDK9/cyclinT1, IC₅₀: 1 nM				CDK14/Cyclin Y, IC₅₀: 1.68 μM	CDK16/Cyclin Y, IC₅₀: 292 nM											98.66%
FN-1501		cdk2/cyclin A, IC₅₀: 2.47 nM		Cdk4/cyclin D1, IC₅₀: 0.85 nM		CDK6/cyclinD1, IC₅₀: 1.96 nM																			98.72%
KH-CB19																	CLK1, IC₅₀: 19.7 nM CLK3, IC₅₀: 530 nM								99.31%
KB-0742	CDK1/cyclin A, IC₅₀: 2980 nM	cdk2/cyclin A, IC₅₀: 397 nM	CDK3/Cyclin E, IC₅₀: 1420 nM	Cdk4/cyclin D1, IC₅₀: 3130 nM	Cdk5/p25, IC₅₀: 1820 nM	CDK6/cyclinD1, IC₅₀: 3950 nM	CDK7/cyclin H, IC₅₀: 1510 nM		CDK9/cyclinT1, IC₅₀: 6 nM																99.38%
PHA-793887	Cdk1/cyclin B, IC₅₀: 60 nM	cdk2/cyclin A, IC₅₀: 8 nM CDK2/cyclinE, IC₅₀: 8 nM		Cdk4/cyclin D1, IC₅₀: 62 nM	Cdk5/p25, IC₅₀: 5 nM		CDK7/cyclin H, IC₅₀: 10 nM		CDK9/cyclinT1, IC₅₀: 138 nM																99.25%
Abemaciclib metabolite M18 hydrochloride				CDK4		CDK6																			98.18%
MC180295	CDK1-Cyclin B, IC₅₀: 138 nM	cdk2-cyclin A, IC₅₀: 233 nM cdk2-cyclin E, IC₅₀: 367 nM	CDK3-Cyclin E, IC₅₀: 399 nM	CDK4-Cyclin D, IC₅₀: 112 nM	cdk5-p35, IC₅₀: 159 nM cdk5-p25, IC₅₀: 186 nM	cdk6-cyclin D3, IC₅₀: 712 nM	CDK7-CycH/MAT1, IC₅₀: 555 nM		CDK9- Cyclin T1, IC₅₀: 5 nM																98.89%
Purvalanol B	cdc2/cyclin B, IC₅₀: 6 nM	cdk2/cyclin A, IC₅₀: 6 nM CDK2/cyclinE, IC₅₀: 9 nM			CDK5/p35, IC₅₀: 6 nM
BS-181 hydrochloride	CDK1/cycB, IC₅₀: 8.1 μM	CDK2/Cyc E, IC₅₀: 0.88 μM		CDK4/Cyc D1, IC₅₀: 33 μM	CDK5/p35NCK, IC₅₀: 3 μM	CDK6/cycD1, IC₅₀: 47 μM	CDK7/CycH/MAT1, IC₅₀: 0.021 μM		CDK9/cycT, IC₅₀: 4.2 μM																99.93%
NU6102	Cdk1/cyclin B, IC₅₀: 9.5 nM	CDK2/cyclin A3, IC₅₀: 5.4 nM		CDK4, IC₅₀: 1.6 μM																					99.23%
LY2857785							CDK7, IC₅₀: 0.246 μM	CDK8, IC₅₀: 0.016 μM	CDK9, IC₅₀: 0.011 μM																99.92%
MeBIO	Cdk1/cyclin B, IC₅₀: 55 μM				Cdk5/p25, IC₅₀: >100 μM																				98.0%
Lerociclib dihydrochloride	CDK1/cyclinB1, IC₅₀: 2.4 μM	cdk2/cyclin A, IC₅₀: 1.5 μM CDK2/cyclinE, IC₅₀: 3.6 μM		Cdk4/cyclin D1, IC₅₀: 1 nM	CDK5/p35, IC₅₀: 832 nM Cdk5/p25, IC₅₀: 1.2 μM	cdk6/cyclin D3, IC₅₀: 2 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2.4 μM		CDK9/Cyclin T, IC₅₀: 28 nM																98.51%
CLK1-IN-1																	CLK1, IC₅₀: 2 nM								98.55%
CP-10						CDK6, DC₅₀: 2.1 nM																			98.41%
YX-2-107						CDK6, IC₅₀: 4.4 nM																			99.22%
CDK2 degrader 1		CDK2																							99.74%
CDK12-IN-3											CDK12, IC₅₀: 491 nM														99.86%
Avotaciclib	CDK1																								99.72%
PROTAC CDK9 Degrader-1									CDK9																99.55%
Rafutrombopag (tautomerism)				CDK4		CDK6																			98.33%
Garcinone C							CDK7																		99.51%
Flavone	CDK1/cyclinB1																								99.85%
CKI-7 free base																Cdc7									99.31%
Leucettine L41																	CLK1, IC₅₀: 71 nM CLK4, IC₅₀: 64 nM								98.98%
Bisindolylmaleimide X hydrochloride		CDK2, IC₅₀: 200 nM																							98.90%
CC-671																	CLK2, IC₅₀: 0.006 μM								99.06%
CDK12-IN-2		CDK2, IC₅₀: >100 μM					CDK7, IC₅₀: >10 μM CDK7, IC₅₀: >10 μM		CDK9, IC₅₀: 16 μM		CDK12, IC₅₀: 52 nM														99.36%
PROTAC CDK12/13 Degrader-1 TFA											CDK12, DC₅₀: 2.2 nM	CDK13, DC₅₀: 2.1 nM													99.12%
ML167			CDK3, IC₅₀: ＞10000 nM														CLK4, IC₅₀: 136 nM CLK1, IC₅₀: 1522 nM CLK2, IC₅₀: 1648 nM								98.62%
CDK9-IN-1									CDK9/CycT1, IC₅₀: 39 nM																98.52%
XY028-133				CDK4		CDK6																			98.62%
CDK5-IN-3		CDK2/CycA, IC₅₀: 18 nM			Cdk5/p25, IC₅₀: 0.6 nM																				99.49%
BRD6989								CDK8, IC₅₀: ~200 nM recombinant CDK8, IC₅₀: ~0.5 μM							recombinant CDK19, IC₅₀: >30 μM										99.56%
DS96432529								CDK8																	99.93%
CDK12-IN-E9		cdk2/cyclin A, IC₅₀: 932 nM					CDK7/Cyclin H/MNAT1, IC₅₀: 1210 nM		CDK9/cyclinT1, IC₅₀: 23.9 nM																99.71%
Samuraciclib hydrochloride dihydrate	CDK1, IC₅₀: 1.8 μM	CDK2, IC₅₀: 578 nM		CDK4, IC₅₀: 49 μM	CDK5, IC₅₀: 9.4 μM	CDK6, IC₅₀: 31 μM	CDK7, IC₅₀: 41 nM		CDK9, IC₅₀: 1.2 μM																99.90%
Tabersonine				CDK4																					98.14%
β-catenin-IN-3				Cdk4/cyclin D1
Palbociclib-d₈				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM																			99.84%
LL-K8-22								CDK8, DC₅₀: 2.52 μM																	99.76%
Riviciclib hydrochloride	CDK1-Cyclin B, IC₅₀: 0.079 μM	cdk2-cyclin A, IC₅₀: 0.224 μM cdk2-cyclin E, IC₅₀: 2.500 μM		cdk4-cyclin D1, IC₅₀: 0.063 μM		cdk6-cyclin D3, IC₅₀: 0.396 μM			CDK9- Cyclin T1, IC₅₀: 0.020 μM CDK9-cyclin H, IC₅₀: 2.900 μM																99.08%
(-)-Enitociclib									CDK9																99.85%
GW8510		CDK2			CDK5																				99.04%
LDC4297							CDK7, IC₅₀: 0.13 nM																		98.14%
CDK9 inhibitor HH1									CDK9																99.69%
AMG 925	CDK1, IC₅₀: 1.9 μM	CDK2, IC₅₀: 375 nM		CDK4, IC₅₀: 3 nM		CDK6, IC₅₀: 8 nM																			99.02%
YJ1206											CDK12	CDK13
(E/Z)-Zotiraciclib hydrochloride		CDK2																							99.90%
Abemaciclib metabolite M20				CDK4		CDK6
CPD-39				CDK4																					98.06%
K00546	Cdk1/cyclin B, IC₅₀: 0.6 nM	cdk2/cyclin A, IC₅₀: 0.5 nM															CLK1, IC₅₀: 8.9 nM CLK3, IC₅₀: 29.2 nM								99.48%
NU6140	CDK1-Cyclin B, IC₅₀: 6.6 μM	cdk2-cyclin A, IC₅₀: 0.41 μM		CDK4-Cyclin D, IC₅₀: 5.5 μM	cdk5-p25, IC₅₀: 15 μM		cdk7-cyclin H, IC₅₀: 3.9 μM																		99.07%
CDK9-IN-2									CDK9, IC₅₀: 5 nM (H929 multiple myeloma cell line)																98.72%
Ipivivint		CDK2, EC₅₀: 1 nM	CDK3, EC₅₀: 7 nM																						99.95%
Senexin C								CDK8/CycC, IC₅₀: 3.6 nM CDK8/CycC, Kd: 1.4 nM							CDK19/CycC, Kd: 2.9 nM										98.82%
CDK-IN-2									CDK9/cyclinT1, IC₅₀: 8 nM																99.27%
CDK7-IN-21							CDK7
RSS0680	CDK1	CDK2		CDK4		CDK6								CDK16/Cyclin Y											99.85%
CDK4/6-IN-15		CDK2, IC₅₀: 3.335 μM		CDK4, IC₅₀: 3 nM		CDK6, IC₅₀: 0.279 μM																			99.32%
CDK2-IN-3		CDK2, IC₅₀: 60 nM
Lacto-N-fucopentaose I		CDK2/cyclinE																							99.92%
PHA-767491	CDK1, IC₅₀: 250 nM	CDK2, IC₅₀: 240 nM			CDK5, IC₅₀: 460 nM				CDK9, IC₅₀: 34 nM																99.85%
YKL-5-124 TFA		CDK2, IC₅₀: 1300 nM					CDK7, IC₅₀: 53.5 nM CDK7/Mat1/CycH, IC₅₀: 9.7 nM		CDK9, IC₅₀: 3020 nM																99.74%
EHT 5372																	CLK1, IC₅₀: 22.8 nM CLK2, IC₅₀: 88.8 nM CLK4, IC₅₀: 59.0 nM								98.12%
Dalpiciclib hydrochloride				CDK4, IC₅₀: 12.4 nM		CDK6, IC₅₀: 9.9 nM																			98.22%
BSJ-01-175											CDK12	CDK13													99.49%
JH-XVI-178								CDK8, IC₅₀: 1 nM							CDK19, IC₅₀: 2 nM										98.87%
CDK8-IN-13								CDK8, IC₅₀: 51.9 nM																	99.14%
RGB-286638 free base	cyclin B1-CDK1, IC₅₀: 2 nM	cyclin E-CDK2, IC₅₀: 3 nM	cyclin E-CDK3, IC₅₀: 5 nM	cyclin D1-CDK4, IC₅₀: 4 nM	p35-CDK5, IC₅₀: 5 nM	cyclin D3-CDK6, IC₅₀: 55 nM	cyclin H-CDK7, IC₅₀: 44 nM		T1-CDK9, IC₅₀: 1 nM																98.87%
S6K1-IN-1																	CLK1								99.71%
Olomoucine		cdk2-cyclin A, IC₅₀: 7 μM cdk2-cyclin E, IC₅₀: 7 μM			cdk5-p35, IC₅₀: 25 μM																				99.87%
LY3177833																Cdc7, IC₅₀: 3.3 nM									99.48%
CDDD11-8									CDK9, Ki: 8 nM																99.62%
CDK2-IN-30		CDK2, IC₅₀: ≤ 20 nM																							98.40%
SRX3177				CDK4, IC₅₀: < 2.5 nM		CDK6, IC₅₀: 3.3 nM																			99.59%
Butyrolactone I	CDK1																								99.80%
AZD5597	CDK1, IC₅₀: 2 nM	CDK2, IC₅₀: 2 nM																							98.09%
Longdaysin							CDK7, IC₅₀: 29 μM																		99.83%
PROTAC CDK4/6 degrader 1				CDK4, DC₅₀: 10.5 nM		CDK6, DC₅₀: 2.5 nM																			98.88%
AS2863619 free base								CDK8, IC₅₀: 0.61 nM							CDK19, IC₅₀: 4.28 nM										99.87%
CDK4/6-IN-2				CDK4, IC₅₀: 2.7 nM		CDK6, IC₅₀: 16 nM																			99.67%
Manzamine A hydrochloride					CDK5, IC₅₀: 1.5 μM																				99.66%
CDK2 degrader 3		CDK2																							99.91%
CLK1-IN-3																	CLK1, IC₅₀: 5 nM CLK2, IC₅₀: 42 nM CLK4, IC₅₀: 108 nM								98.54%
GSK-3 inhibitor 3		CDK2, IC₅₀: 0.22 μM			CDK5, IC₅₀: 1.3 μM																				98.72%
BSJ-5-63							CDK7		CDK9		CDK12														99.97%
Ryuvidine				CDK4, IC₅₀: 6.0 μM																					99.40%
BGG463		CDK2																							98.0%
CDK1-IN-1	CDK1/cycB, IC₅₀: 161.2 nM																								99.33%
CDK8-IN-11								CDK8, IC₅₀: 46 nM																	98.20%
Atuveciclib Racemate									CDK9																98.48%
CDK9-IN-7				CDK4/cyclin D, IC₅₀: 148 nM		CDK6/cyclinD, IC₅₀: 145 nM			CDK9/cyclinT1, IC₅₀: 11 nM																98.05%
Avotaciclib hydrochloride	CDK1																								99.75%
CDK9-IN-13	CDK1, IC₅₀: 0.14 μM	CDK2, IC₅₀: 0.72 μM					CDK7, IC₅₀: 0.40 μM		CDK9, IC₅₀: <3 nM		CDK12, IC₅₀: 0.055 μM														99.94%
Avotaciclib trihydrochloride	CDK1																								99.60%
TP-1287									CDK9
DB0614						CDK6								CDK16/Cyclin Y											98.80%
CPD-10				CDK4
CDK2 degrader 5		CDK2																							99.17%
Abemaciclib metabolite M18				CDK4		CDK6																			98.01%
MU1210																	CLK1, IC₅₀: 8 nM CLK2, IC₅₀: 20 nM CLK4, IC₅₀: 12 nM								99.50%
PROTAC CDK12/13 Degrader-1											CDK12, DC₅₀: 2.2 nM	CDK13, DC₅₀: 2.1 nM													98.01%
Desmethylglycitein	CDK1	CDK2																							98.98%
DD-03-156																					CDK17				99.90%
TMX-2172		CDK2, IC₅₀: 6.5 nM			CDK5, IC₅₀: 6.8 nM																				99.38%
CDK7-IN-4							CDK7																		98.87%
LDC4297 hydrochloride							CDK7, IC₅₀: 0.13 nM																		98.23%
ZLC491											CDK12	CDK13													98.51%
Ribociclib succinate hydrate				CDK4, IC₅₀: 10 nM		CDK6, IC₅₀: 39 nM																			99.94%
CDK9-IN-8									CDK9, IC₅₀: 12 nM																99.16%
Samuraciclib hydrochloride hydrate	CDK1, IC₅₀: 1.8 μM	CDK2/cycE1, IC₅₀: 578 nM		CDK4, IC₅₀: 49 μM	CDK5, IC₅₀: 9.4 μM	CDK6, IC₅₀: 34 μM	CDK7/CycH/MAT1, IC₅₀: 41 nM		CDK9, IC₅₀: 1.2 μM																99.88%
(E/Z)-Zotiraciclib citrate		CDK2																							99.83%
Casein Kinase inhibitor A86							CDK7, Kd: 0.31 nM		CDK9, Kd: 5.4 nM																99.26%
BS-194	CDK1, IC₅₀: 30 nM	CDK2, IC₅₀: 3 nM			CDK5, IC₅₀: 30 nM		CDK7, IC₅₀: 250 nM		CDK9, IC₅₀: 90 nM																99.36%
Aristolochic acid D		CDK2, IC₅₀: 25 μM																							99.74%
DB1113				CDK4						CDK11B															99.22%
5-Iodo-indirubin-3'-monoxime	Cdk1/cyclin B, IC₅₀: 25 nM				Cdk5/p25, IC₅₀: 20 nM																				99.50%
NVP-LCQ195	Cdk1/cyclin B, IC₅₀: 2 nM	cdk2/cyclin A, IC₅₀: 2 nM CDK2/cyclinE, IC₅₀: 5 nM	CDK3/Cyclin E, IC₅₀: 42 nM		Cdk5/p25, IC₅₀: 1 nM CDK5/p35, IC₅₀: 1 nM	cdk6/cyclin D3, IC₅₀: 187 nM	CDK7/Cyclin H/MAT1, IC₅₀: 3564 nM		CDK9/cyclinT1, IC₅₀: 15 nM																98.81%
NU2058	CDK1, IC₅₀: 26 μM	CDK2, IC₅₀: 17 μM CDK2, Ki: 12 μM																							99.66%
HS-243																	CLK4, IC₅₀: 662 nM								99.95%
CDK1-IN-2	CDK1, IC₅₀: 5.8 μM																								98.89%
FIT-039									CDK9/cyclinT1, IC₅₀: 5.8 μM																99.56%
AT7519 Hydrochloride	Cdk1/cyclin B, IC₅₀: 210 nM	cdk2/cyclin A, IC₅₀: 47 nM		Cdk4/cyclin D1, IC₅₀: 100 nM	CDK5/p35, IC₅₀: 13 nM	cdk6/cyclin D3, IC₅₀: 170 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM		CDK9/Cyclin T, IC₅₀: 10 nM																99.42%
(S)-Roscovitine	CDK1, IC₅₀: ≤1 μM	CDK2, IC₅₀: ≤1 μM			CDK5, IC₅₀: ≤1 μM		CDK7, IC₅₀: ≤1 μM		CDK9, IC₅₀: ≤1 μM																99.15%
Cdk5i peptide					Cdk5/p25, Kd: 0.17 μM CDK5, Kd: 15.72 μM																				99.83%
CDK9-IN-11									CDK9
HEMTAC CDK4/6 degrader 1				CDK4		CDK6																			98.18%
ON-013100				Cdk4/cyclin D1																					99.66%
CDK12-IN-5		CDK2/cyclinE, IC₅₀: 173 μM							CDK9/cyclinT1, IC₅₀: 127 μM		CDK12, IC₅₀: 23.9 nM														99.01%
THZ1-R							CDK7, IC₅₀: 146 nM																		98.06%
NU6027	CDK1, Ki: 2.5 μM	CDK2, Ki: 1.3 μM																							99.04%
CDK12-IN-6		CDK2/cyclinE, IC₅₀: >20 μM							CDK9/cyclinT1, IC₅₀: >20 μM		CDK12, IC₅₀: 1.19 μM														98.09%
CDK8/19-IN-1								CDK8/CycC, IC₅₀: 0.46 nM	CDK9, IC₅₀: 270 nM						CDK19/CycC, IC₅₀: 0.99 nM										98.03%
CDK4 degrader 1				CDK4																					99.50%
HTH-01-091							CDK7, IC₅₀: 1230 nM																		98.64%
CK7		CDK2							CDK9																99.72%
Vanicoside B			CDK3																						99.82%
CDD-2807																	CLK4, IC₅₀: 85 nM CLK2, IC₅₀: 101 nM CLK1, IC₅₀: 116 nM								99.52%
NecroIr1				CDK4																					98.02%
Isosilybin B		CDK2		CDK4																					99.32%
CDK9-IN-12									CDK9/cyclinT1, IC₅₀: 5.41 nM																99.65%
CDK2-IN-31		CDK2																							98.22%
Lerociclib	CDK1/cyclinB1, IC₅₀: 2.4 μM	cdk2/cyclin A, IC₅₀: 1.5 μM CDK2/cyclinE, IC₅₀: 3.6 μM		Cdk4/cyclin D1, IC₅₀: 1 nM	CDK5/p35, IC₅₀: 0.832 μM Cdk5/p25, IC₅₀: 1.2 μM	cdk6/cyclin D3, IC₅₀: 2 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2.4 μM		CDK9/Cyclin T, IC₅₀: 28 nM																98.35%
KH-CB20																	CLK1, IC₅₀: 16.5 nM CLK3, IC₅₀: 488 nM								99.80%
PROTAC CDK9 degrader-2									CDK9, IC₅₀: 17 μM (MCF-7 cells)																99.22%
ABC1183									CDK9- Cyclin T1, IC₅₀: 321 nM																99.62%
Cdk1/2 Inhibitor III	Cdk1/cyclin B, IC₅₀: 0.6 nM	CDK2/cyclinA, IC₅₀: 0.5 nM																							99.69%
CDK2 degrader 4		CDK2																							99.71%
7BIO					CDK5																				99.20%
PROTAC CDK9 degrader-9									CDK9																99.25%
CGP-82996	CDK1/cyclinB, IC₅₀: >100 μM	CDK2/cyclinA, IC₅₀: >50 μM CDK2/cyclin E, IC₅₀: >50 μM		Cdk4/cyclin D1, IC₅₀: 1.5 μM CDK4/cyclin D2, IC₅₀: >50 μM	CDK5/p35, IC₅₀: 25 μM	CDK6/cyclinD1, IC₅₀: 5.6 μM Cdk6/cyclin D2, IC₅₀: >50 μM																			98.12%
CDK2/4/6-IN-2		CDK2		CDK4		CDK6																			98.20%
PNU-292137	CDK1/cyclinB, IC₅₀: 270 nM	CDK2/cyclinA, IC₅₀: 37 nM CDK2/cyclin E, IC₅₀: 92 nM		CDK4/cyclinD1, IC₅₀: >10000 nM	Cdk5/p25, IC₅₀: 114 nM																				99.95%
Ca2+ channel agonist 1		CDK2, EC₅₀: 3.34 μM																							99.71%
CA224		cdk2-cyclin A, IC₅₀: 521 μM		cdk4-cyclin D1, IC₅₀: 6.2 μM																					99.94%
BI-1622										CDK11B															98.97%
CAN508	Cdk1/cyclin B, IC₅₀: 44 μM	CDK2/cyclinE, IC₅₀: 20 μM cdk2/cyclin A, IC₅₀: 69 μM		Cdk4/cyclin D1, IC₅₀: 13.5 μM			CDK7/cyclin H, IC₅₀: 26 μM		CDK9/cyclinT1, IC₅₀: 0.35 μM																99.59%
Cimpuciclib tosylate				CDK4, IC₅₀: 0.49 nM		CDK6, IC₅₀: 9.56 nM																			99.65%
Voruciclib hydrochloride	CDK1/cycB, Ki: 5.4 nM CDK1/cyc A, Ki: 9.1 nM			CDK4/Cyc D1, Ki: 3.96 nM		CDK6/cycD1, Ki: 2.92 nM			CDK9/CycT1, Ki: 1.68 nM CDK9/cyc T2, Ki: 0.626 nM																99.23%
GW297361	yeast Cdk1, IC₅₀: 20 nM human CDK1, IC₅₀: 30 nM	human CDK2, IC₅₀: 1.9 nM		human CDK4, IC₅₀: 300 nM					human CDK9, IC₅₀: 10 nM									yeast Pho85, IC₅₀: 400 nM							98.13%
CDK9-IN-10									CDK9																98.09%
PNU112455A hydrochloride		CDK2, Km: 3.6 μM			CDK5, Km: 3.2 μM																				99.56%
CDK9/EZH2-IN-1									CDK9, IC₅₀: 83.9 nM
CDK4/6-IN-9						CDK6/cyclinD1, IC₅₀: 905 nM																			99.46%
YKL-1-116							CDK7																		98.67%
CDK8 ligand 1								CDK8																	98.0%
NSC693868	Cdk1/cyclin B, IC₅₀: 600 nM				Cdk5/p25, IC₅₀: 400 nM																				99.0%
CDK1-IN-6	CDK1																								99.96%
TMX-2039	CDK1, IC₅₀: 2.6 nM	CDK2, IC₅₀: 1.0 nM		CDK4, IC₅₀: 52.1 nM	CDK5, IC₅₀: 0.5 nM	CDK6, IC₅₀: 35 nM	CDK7, IC₅₀: 32.5 nM		CDK9, IC₅₀: 25 nM																99.42%
NSC 625987				CDK4/D1, IC₅₀: 0.2 μM																					98.01%
CLK1/2-IN-1																	CLK1, IC₅₀: 16 nM CLK2, IC₅₀: 45 nM								99.87%
(R)-DRF053 dihydrochloride	CDK1/cyclinB1, IC₅₀: 220 nM				Cdk5/p25, IC₅₀: 80 nM																				99.30%
(R)-(+)-O-Demethylbuchenavianine	CDK1, IC₅₀: 1.1 μM				CDK5, IC₅₀: 0.95 μM																				98.67%
AT7519 TFA	Cdk1/cyclin B, IC₅₀: 210 nM	cdk2/cyclin A, IC₅₀: 47 nM		Cdk4/cyclin D1, IC₅₀: 100 nM	CDK5/p35, IC₅₀: 13 nM	cdk6/cyclin D3, IC₅₀: 170 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM		CDK9/Cyclin T, IC₅₀: 10 nM
CDK8-IN-1								CDK8, IC₅₀: 3 nM																	99.77%
Samuraciclib	CDK1, IC₅₀: 1.8 μM	CDK2/cycE1, IC₅₀: 578 nM		CDK4, IC₅₀: 49 μM	CDK5, IC₅₀: 9.4 μM	CDK6, IC₅₀: 34 μM	CDK7/CycH/MAT1, IC₅₀: 41 nM		CDK9, IC₅₀: 1.2 μM																99.55%
CDK2-IN-22		CDK2, IC₅₀: 64.42 nM																							98.64%
CDK6/PIM1-IN-1 hydrochloride				CDK4, IC₅₀: 3.6 nM		CDK6, IC₅₀: 39 nM																			99.38%
CDK1/Cyc B-IN-1	CDK1-Cyclin B, IC₅₀: 97 nM																								98.47%
GSK-3 inhibitor 4		CDK2, IC₅₀: 0.47 μM			CDK5, IC₅₀: 0.68 μM																				98.77%
LA-CB1				CDK4		CDK6																			98.20%
CDK2-IN-40		CDK2/cyclinE, IC₅₀: 10 nM																							99.80%
CDK9-IN-14									CDK9, IC₅₀: 6.92 nM																99.91%
RGB-286147	CDK1/cyclinB, IC₅₀: 48 nM	CDK2/E, IC₅₀: 15 nM		CDK4/D1, IC₅₀: 839 nM		cdk6/cyclin D3, IC₅₀: 232 nM																			98.60%
CDK4/6-IN-12				CDK4, IC₅₀: 592.3 nM		CDK6, IC₅₀: 3090 nM																			99.76%
ZDLD20				CDK4/CycD3, IC₅₀: 6.51 μM																					99.84%
Damulin B				CDK4		CDK6
AG-012986	Cdk1/cyclin B, Ki: 44 nM	cdk2/cyclin A, Ki: 94 nM		CDK4, Ki: 9.2 nM	CDK5/p35, IC₅₀: 22 nM				CDK9/Cyclin T, IC₅₀: 4 nM																99.78%
NecroIr2				CDK4																					98.99%
CDK7-IN-1							CDK7, IC₅₀: 100 nM																		98.91%
Romaciclib								CDK8/CycC, IC₅₀: 4.4 nM	CDK9/cycT, IC₅₀: 1070 nM						CDK19/CycC, IC₅₀: 10.4 nM
BS-181	CDK1/cycB, IC₅₀: 8.1 μM	CDK2/Cyc E, IC₅₀: 0.88 μM		CDK4/Cyc D1, IC₅₀: 33 μM	CDK5/p35NCK, IC₅₀: 3 μM	CDK6/cycD1, IC₅₀: 47 μM	CDK7/CycH/MAT1, IC₅₀: 0.021 μM		CDK9/cycT, IC₅₀: 4.2 μM																98.10%
(S)-LY3177833 hydrate																Cdc7
LY3177833 monhydrate																Cdc7, IC₅₀: 3.3 nM									99.76%
IV-361		CDK2, Ki: ≥1000 nM					CDK7, Ki: ≤50 nM																		99.60%
YJ9069											CDK12	CDK13
CDK-TCIP1									CDK9
Akt1&PKA-IN-2		CDK2^a, IC₅₀: 0.69 μM
Manzamine A					CDK5, IC₅₀: 1.5 μM																				98.2%
DDO-6079																CDC37
(R)-CDK2 degrader 6		CDK2, DC₅₀: 27 nM
Tambiciclib dimaleate	CDK1/cyclinB, IC₅₀: 5410 nM	CDK2/cyclinA, IC₅₀: 6850 nM	CDK3/cyclin E1, IC₅₀: >10,000 nM		Cdk5/p25, IC₅₀: 6950 nM		CDK7/Cyclin H/MNAT1, IC₅₀: 3700 nM	CDK8/cyclin C, IC₅₀: >10,000 nM	CDK9/cyclinT1, IC₅₀: 1 nM	CDK11, IC₅₀: >10,000 nM			CDK14/Cyclin Y, IC₅₀: 2710 nM	CDK16/Cyclin Y, IC₅₀: 195 nM
Bohemine		CDK2/cyclinE, IC₅₀: 4.6 μM cdk2/cyclin A, IC₅₀: 83 μM							CDK9/cyclinT1, IC₅₀: 2.7 μM																98.93%
CDK6/PIM1-IN-1	CDK1/cyclinB, IC₅₀: >10 μM	CDK2/cyclinA, IC₅₀: 2.274 μM	CDK3/Cyclin E, IC₅₀: >10 μM	Cdk4/cyclin D1, IC₅₀: 3.6 nM	Cdk5/p25, IC₅₀: >10 μM	CDK6/cyclinD1, IC₅₀: 39 nM	CDK7/Cyclin H/MNAT1, IC₅₀: 393 nM		CDK9/cyclinT1, IC₅₀: 440 nM		CDK12/Cyclin K, IC₅₀: >10 μM	CDK13/Cyclin K, IC₅₀: >10 μM
Multi-target kinase inhibitor 2		CDK2, IC₅₀: 204 nM																							99.82%
JA397													CDK14/Cyclin Y, EC₅₀: 27.1 nM	CDK16/Cyclin Y, EC₅₀: 39.0 nM
CDK8-IN-12								CDK8, Ki: 14 nM																	99.74%
(E/Z)-BIO-acetoxime	CDK1/cyclinB, IC₅₀: 63 μM	CDK2/cyclinA, IC₅₀: 4.3 μM			Cdk5/p25, IC₅₀: 2.4 μM																				99.0%
AMG 925 (HCl)	CDK1, IC₅₀: 1.9 μM	CDK2, IC₅₀: 375 nM		CDK4, IC₅₀: 3 nM		CDK6, IC₅₀: 8 nM
CDK5-IN-1					CDK5, IC₅₀: < 10 nM																				98.47%
CKI-7																Cdc7									98.41%
PT-262		CDK2																							99.21%
CDK7-IN-28		cdk2/cyclin A, IC₅₀: 6224 nM					CDK7/Cyclin H/MNAT1, IC₅₀: ＜5 nM					CDK13/Cyclin K, IC₅₀: 152 nM
Sinigrin hydrate				CDK4		CDK6																			99.77%
Abemaciclib metabolite M20-d₈				CDK4		CDK6																			99.26%
Akt1&PKA-IN-1		CDK2, IC₅₀: 9.8 μM
HQY1428											CDK12
PPA-037											CDK12/Cyclin K
Palbociclib dihydrochloride				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM
Palbociclib orotate				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM
Cimpuciclib				CDK4, IC₅₀: 0.49 nM		CDK6, IC₅₀: 9.56 nM
Rafutrombopag				CDK4		CDK6
CDK1-IN-5	CDK1, IC₅₀: 42.19 nM	CDK2, IC₅₀: 188.71 nM			CDK5, IC₅₀: 354.15 nM
ZLMT-12		CDK2, IC₅₀: 0.011 μM							CDK9, IC₅₀: 0.002 μM
CDK7-IN-2 hydrochloride hydrate							CDK7
BS-181 dihydrochloride		CDK2, IC₅₀: 880 nM			CDK5, IC₅₀: 3000 nM		CDK7, IC₅₀: 21 nM		CDK9, IC₅₀: 4200 nM
CDK1-IN-3	CDK1, IC₅₀: 36.8 nM	CDK2, IC₅₀: 305.17 nM			CDK5, IC₅₀: 369.37 nM
CDK4/6-IN-3	CDK1, Ki: 110 nM			CDK4, Ki: 0.3 nM		CDK6, Ki: 2.2 nM
HDAC1/2 and CDK2-IN-1		CDK2, IC₅₀: 0.80 nM
FN-1501-propionic acid		CDK2							CDK9
OTS964										CDK11B, Kd: 40 nM
CDK6/9-IN-1						CDK6, IC₅₀: 40.5 nM			CDK9, IC₅₀: 39.5 nM
Amantadine sulfate		CDK2
CDK7-IN-11							CDK7, IC₅₀: 4.2 nM
Senexin A hydrochloride								CDK8, IC₅₀: 280 nM CDK8, Kd: 0.83 μM							CDK19, Kd: 0.31 μM
CDK9-IN-9		CDK2, IC₅₀: 155 nM							CDK9, IC₅₀: 1.8 nM
CDK9-IN-34									CDK9, IC₅₀: 0.25 μM
ZLHQ-5f		CDK2/CycA2, IC₅₀: 0.145 μM
CDK2 degrader 7	CDK1, DC₅₀: 2130 nM	CDK2, DC₅₀: 13 nM (MKN1cells) CDK2, DC₅₀: 17 nM (TOV21G cells)
Anticancer agent 264	CDK1/cyclinB1	CDK2/cyclinE
CDK2-IN-37		CDK2
CDK7-IN-29							CDK7, IC₅₀: 1.4 nM
CDK8-IN-5								CDK8, IC₅₀: 72 nM
CDK4/6-IN-21 maleate				CDK4, IC₅₀: 3.88 nM		CDK6, IC₅₀: 3.31 nM
Haspin-IN-2																	CLK1, IC₅₀: 445 nM
PARP1/CDK12-IN-1											CDK12, IC₅₀: 285 nM
ARUK2010694		CDK2		CDK4		CDK6
BLINK15	CDK1/Cly Y, IC₅₀: 35.84 nM	CDK2/ClyA2, IC₅₀: 44.12 nM			CDK5/p35, IC₅₀: 29.34 nM Cdk5/p25, IC₅₀: 12.08 nM				CDK9/Cyclin T, IC₅₀: 74.63 nM
ZDLD13				CDK4/CycD3, IC₅₀: 0.38 μM
PROTAC FLT3/CDKs degrader-1		CDK2, DC₅₀: 18.73 nM
CDK-IN-18		CDK2		CDK4		CDK6
ALK-IN-29		CDK2
CDK4/6/HDAC-IN-1	CDK1, IC₅₀: 55.6 nM			CDK4, IC₅₀: 7.23 nM		CDK6, IC₅₀: 13.2 nM CDK6, IC₅₀: 48.38 nM
CDK7-IN-30	CDK1, IC₅₀: >10000.00 nM	CDK2, IC₅₀: 734.55 nM	CDK3, IC₅₀: 370.40 nM	CDK4, IC₅₀: 644.80 nM	CDK5, IC₅₀: 3678.50 nM	CDK6, IC₅₀: 1345.50 nM	CDK7, IC₅₀: 7.21 nM		CDK9, IC₅₀: 704.3 nM
CDK2-IN-41		CDK2
CDK4/6/BRD4-IN-1				CDK4, IC₅₀: 85 nM		CDK6, IC₅₀: 106 nM
CDK9-IN-22		cdk2/cyclin A, IC₅₀: 876.2 nM							CDK9/cyclinT1, IC₅₀: 10.4 nM
CDK7-IN-27		CDK2, IC₅₀: 19.4 nM					CDK7, IC₅₀: 3 nM
CDK4/6-IN-19				CDK4, IC₅₀: 0.2 nM		CDK6, IC₅₀: 5.0 nM
PSTAIR																CDC28
Antitumor agent-174	CDK1/cyclinB1
CDK8-IN-18								CDK8, IC₅₀: 43 μM
M1-20	CDK1
Ulecaciclib		cdk2/cyclin A, Ki: 0.62 μM		Cdk4/cyclin D1, Ki: 0.2 nM		cdk6/cyclin D3, Ki: 3 nM	cdk7-cyclin H, Ki: 0.63 μM
BLINK11	CDK1/Cly Y, IC₅₀: 39.34 nM	CDK2/ClyA2, IC₅₀: 83.43 nM			CDK5/p35, IC₅₀: 17.09 nM Cdk5/p25, IC₅₀: 14.69 nM				cdk9-cyclin T, IC₅₀: 83.43 nM
GSK3-IN-10				CDK4, IC₅₀: 3800 nM													CLK1, IC₅₀: 620 nM CLK4, IC₅₀: 760 nM CLK2, IC₅₀: 800 nM
CDK2-IN-14-d₃		CDK2
CDK2/4-IN-1		CDK2		CDK4
KI-ARv-03									CDK9, IC₅₀: 0.15 μM
CDK1-IN-4	CDK1, IC₅₀: 44.52 nM	CDK2, IC₅₀: 621.93 nM			CDK5, IC₅₀: 135.22 nM
Isosilybin B (Standard)		CDK2		CDK4
CAIX/CDK-2-IN-1		CDK2, IC₅₀: 0.32 μM
CDK2-IN-28		CDK2, Ki: 1 nM ([1])			CDK5, Ki: 15.8 nM ([1])		CDK7, Ki: 54.7 nM ([1])		CDK9, Ki: 12.8 nM ([1])
PROTAC CDK9/CycT1 Degrader-2									CDK9, IC₅₀: 45 nM
ARUK2010489		CDK2		CDK4		CDK6
CDK4/6-IN-23						CDK6, IC₅₀: 11 nM
VEGFR-2-IN-69		CDK2		CDK4		CDK6
CDK6/9-IN-2						CDK6, IC₅₀: 15 nM			CDK9, IC₅₀: 22 nM
KB-0742 hydrochloride	CDK1/cyclin A, IC₅₀: 2980 nM	cdk2/cyclin A, IC₅₀: 397 nM	CDK3/Cyclin E, IC₅₀: 1420 nM	Cdk4/cyclin D1, IC₅₀: 3130 nM	Cdk5/p25, IC₅₀: 1820 nM	CDK6/cycD1, IC₅₀: 3950 nM	CDK7/cyclin H, IC₅₀: 1510 nM	CDK8/cyclin C, IC₅₀: >10000 nM	CDK9/cyclinT1, IC₅₀: 6 nM
CDK19 Probe 1															CDK19, IC₅₀: 1.01 μM
PROTAC CDK4/6/9 degrader 1				CDK4, DC₅₀: 0.71 nM (MDA-MB-231 cells) CDK4, DC₅₀: 0.79 nM (CAL51 cells)		CDK6, DC₅₀: 0.44 nM (MDA-MB-231 cells) CDK6, DC₅₀: 0.61 nM (CAL51 cells)			CDK9, DC₅₀: 0.52 nM (MDA-MB-231 cells) CDK9, DC₅₀: 0.51 nM (CAL51 cells)
dCDK9-202									CDK9, DC₅₀: 3.5 nM
Apoptosis inducer 50	CDK1
CDK-IN-12				CDK4, IC₅₀: <20 nM		CDK6, IC₅₀: <20 nM
HDAC1/CDK7-IN-1							CDK7, IC₅₀: 893 nM
TMX-2138	CDK1/cyclinB, IC₅₀: 8.7 nM	CDK2/cyclinA, IC₅₀: 10.9 nM		CDK4/cyclinD1, IC₅₀: 901 nM	Cdk5/p25, IC₅₀: 7.0 nM	CDK6/cyclinD1, IC₅₀: 465 nM	CDK7/cyclin H, IC₅₀: 286 nM		CDK9/cyclinT1, IC₅₀: 25.7 nM
CDK12-IN-4		CDK2/cyclinE, IC₅₀: >20 μM							CDK9/cyclinT1, IC₅₀: >20 μM		CDK12, IC₅₀: 0.641 μM
USP10-IN-4				CDK4
SLM6									CDK9/cyclinT1, IC₅₀: 133 nM
NUAK1-IN-1				CDK4
P-gp/CDK2-IN-1		CDK2
Cdc7-IN-15																Cdc7
CDK9-IN-19									CDK9/cyclinT1, IC₅₀: 2 nM
Haspin-IN-1																	CLK1, IC₅₀: 221 nM
CDK8-IN-10								CDK8, IC₅₀: 8.25 nM
KY19334	CDK1
CDK2/4/6-IN-1		CDK2, IC₅₀: 2.5 nM		CDK4, IC₅₀: 23.7 nM		CDK6, IC₅₀: 44.3 nM
CDK9-IN-23									CDK9, IC₅₀: <20 nM
CDK7/9-IN-1							CDK7, IC₅₀: 5.74-65.6 nM		CDK9, IC₅₀: 2.14 μM
Anticancer agent 30		CDK2
PROTAC CDK9 degrader-6									CDK9₄₂, DC₅₀: 0.03 μM CDK9₅₅, DC₅₀: 0.05 μM
CDK4/6-IN-7				CDK4, IC₅₀: 1.58 nM		CDK6, IC₅₀: 4.09 nM
CLZX-205									CDK9, IC₅₀: 2.9 nM
PI3Kα-IN-26		CDK2/CycA2, IC₅₀: 3.96 μM						CDK8/cyclin C, IC₅₀: 137.20 nM
CDK4/6-IN-16				CDK4, IC₅₀: 13 nM
CDK4/9-IN-1				CDK4, IC₅₀: 23 nM					CDK9, IC₅₀: 12 nM
CDK9-IN-44									CDK9, IC₅₀: 7.6 μM
CDK2-IN-26		CDK2
CDK4/6-IN-10				CDK4, IC₅₀: 22 nM		CDK6/cyclinD1, IC₅₀: 10 nM
CDK2-IN-42											CDK12
KDM1/CDK1-IN-1	CDK1, IC₅₀: 0.078 ± 2. μM
CDK7-IN-8							CDK7, IC₅₀: 54.29 nM
CDK7-IN-7							CDK7, IC₅₀: <50 nM
CDK8-IN-6								CDK8, Kd: 13 nM
CDK9-IN-28									CDK9/cyclinT1
CDK4/6-IN-8				CDK4, IC₅₀: 5.01 nM		CDK6, IC₅₀: 3.97 nM
PF-06842874				CDK4/cyclinD1, Ki: 62 nM		cdk6/cyclin D3, Ki: 130 nM
CDK7-IN-5							CDK7, IC₅₀: <100 nM
PROTAC CDK9 degrader-5									CDK9₄₂, DC₅₀: 0.10 μM CDK9₅₅, DC₅₀: 0.14 μM
CDK8/19-IN-3								CDK8							CDK19
CDKI-83	CDK1/B, Ki: 72 nM	CDK2/E, Ki: 232 nM		CDK4/D, Ki: 290 nM			CDK7/H, Ki: 405 nM		CDK9/T1, Ki: 21 nM
CDK5-IN-4		CDK2, IC₅₀: 6.24 ± 2.8 μM			CDK5, IC₅₀: 9.8 ± 2.29 μM				CDK9, IC₅₀: 1.76 ± 0.3 μM
G721-0282				CDK4		CDK6
CDK2-IN-48		CDK2
CDK2-IN-8		CDK2, IC₅₀: 1.74 μM
(S)-LY3177833																Cdc7
CDK12/13-IN-2											CDK12, IC₅₀: 15.5 nM	CDK13, IC₅₀: 12.2 nM
Cdc7-IN-19																Cdc7, IC₅₀: 1.49 nM
CDK1/2/4-IN-1	CDK1, IC₅₀: 1.47	CDK2, IC₅₀: 0.78		CDK4, IC₅₀: 0.87
CDK9-IN-42									CDK9, IC₅₀: 3.8 nM
CGP-74514 hydrochloride	CDK1/cyclinB1, IC₅₀: 25 nM
SZ-015268							CDK7, IC₅₀: 23.56 nM
CDK2-IN-12		CDK2, IC₅₀: 11.6 μM							CDK9, IC₅₀: >12.5 μM
CP-07									CDK9
CDK7-IN-31							CDK7, Kd: 0.18 nM
SHP2/CDK4-IN-1				CDK4, IC₅₀: 18.2 ± 1.3 nM
CDK4/6-IN-20				CDK4, IC₅₀: 1.9 nM		CDK6, IC₅₀: 14.2 nM
CDK2-IN-47	CDK1, IC₅₀: 1.80 μM	CDK2, IC₅₀: 0.21 μM		CDK4, IC₅₀: > 10 μM		CDK6, IC₅₀: > 10 μM	CDK7, IC₅₀: 8.70 μM		CDK9, IC₅₀: 2.30 μM
CDK9 degrader-1									CDK9, DC₅₀: 0.4073 μM
Multi-kinase-IN-4		CDK2, IC₅₀: 2.09 μM
Cdc7-IN-12																Cdc7, IC₅₀: <1 nM
YX0798									CDK9, Kd: 0.28 nM
YJZ5118											CDK12	CDK13
CDK2-IN-44		CDK2
CDK-IN-14		CDK2/CycA2, IC₅₀: 0.097 μM
CDK2-IN-18		CDK2/cyclinE, IC₅₀: 8 nM		Cdk4/cyclin D1, IC₅₀: 46 nM
CDK7-IN-32							CDK7
EGFR-IN-45		CDK2, IC₅₀: 1.6 μM
CDK7-IN-20	CDK1, IC₅₀: 3375 nM	CDK2, IC₅₀: 823 nM	CDK3, IC₅₀: 1837 nM		CDK5, IC₅₀: >10,000 nM	CDK6, IC₅₀: 950 nM	CDK7, IC₅₀: 4 nM		CDK9, IC₅₀: 526 nM		CDK12, IC₅₀: >10,000 nM
CDK9-IN-33		CDK2, IC₅₀: 316.30 nM		CDK4, IC₅₀: 1771.00 nM		CDK6, IC₅₀: >10000 nM	CDK7, IC₅₀: 160 nM		CDK9, IC₅₀: 17.44 nM
CDK8-IN-19		CDK2/CycA2, IC₅₀: 1.13 μM						CDK8/cyclin C, IC₅₀: 25.08 nM
LZ9	CDK1 cyclin B1/CDC2
Palbociclib-C4-Boc				CDK4		CDK6
3-Methylthienyl-carbonyl-JNJ-7706621	CDK1/cyclinB, IC₅₀: 6.4 nM	CDK2/cyclinA, IC₅₀: 2 nM		CDK4, IC₅₀: 0.11 μM
CDK-IN-9		CDK2/E, IC₅₀: 4 nM			Cdk5/p25, IC₅₀: 39 nM				CDK9/T1, IC₅₀: 20 nM		CDK12/K, IC₅₀: 64 nM	CDK13/K, IC₅₀: 22 nM
Autophagy agonist-1				CDK4
CDK9 autophagic degrader 1									CDK9
Wogonin (Standard)								CDK8
ARN25499																Cdc42
CLK1/2-IN-3																	CLK1, IC₅₀: 1.1 nM CLK2, IC₅₀: 2.1 nM
Carbonic anhydrase inhibitor 33						CDK6, IC₅₀: 0.069 μM
CDK2-IN-29		CDK2, IC₅₀: 96 nM		CDK4, IC₅₀: 360 nM
Carbonic anhydrase inhibitor 14		CDK2, IC₅₀: 20.3 μM
CDC20/HSP90-IN-1	CDK1/cyclinB1
CDK9-IN-37									CDK9, EC₅₀: 5.5 nM
Cdc7-IN-14																Cdc7, IC₅₀: <1 nM
YY173				CDK4, IC₅₀: 7.7 nM		CDK6, IC₅₀: 88 nM
Multi-kinase-IN-6		CDK2, IC₅₀: 0.71 μM
FLT3/ITD-IN-4														CDK16/Cyclin Y, EC₅₀: 1768 nM
Anticancer agent 29	CDK1/cyclinB1, IC₅₀: 0.127 μM	CDK2/cyclinE, IC₅₀: 0.054 μM		CDK4, IC₅₀: 0.129 μM		CDK6, IC₅₀: 0.396 μM
CDK9-IN-36									CDK9, IC₅₀: 1.2 nM
CDK9-IN-24									CDK9
CDK2-IN-20		CDK2/cyclinE, IC₅₀: 0.219 μM
CDK9-IN-40									CDK9, IC₅₀: 5.5 nM
XL413 hydrochloride																Cdc7, IC₅₀: 3.4 nM
CDK2-IN-7		CDK2/cyclinE, IC₅₀: 50 nM
CDK2/9-IN-1		CDK2, IC₅₀: 0.004 μM							CDK9, IC₅₀: 0.009 μM
CDK8/19-IN-2								CDK8/CycC, IC₅₀: 2.08 nM							CDK19/CycC, IC₅₀: 2.49 nM
CDK2-IN-45		CDK2, IC₅₀: 0.64 μM
CDK9/HDAC1/HDAC3-IN-1									CDK9, EC₅₀: 0.17 μM
CDK12-IN-8											CDK12
CGP-74514 dihydrochloride	CDK1/cyclinB1, IC₅₀: 25 nM
Aloisine RP106	Cdk1/cyclin B, IC₅₀: 0.7 μM				Cdk5/p25, IC₅₀: 1.5 μM
Aloisine A	CDK1/cyclinB, IC₅₀: 0.15 μM	CDK2/cyclinA, IC₅₀: 0.12 μM CDK2/cyclinE, IC₅₀: 0.4 μM			CDK5/p35, IC₅₀: 0.16 μM
CDK9-IN-41									CDK9, IC₅₀: 192.81 nM																98.84%
CDK7-IN-16							CDK7, IC₅₀: 1~10 nM
Dalpiciclib isethionate				CDK4		CDK6
FLT3/CDK4-IN-1				CDK4, IC₅₀: 7 nM
BMI-1026	CDK1, IC₅₀: 2.3 nM
CDK2-IN-43		Cdk2/cyclin E2, IC₅₀: 6 nM
CDK12-IN-7		CDK2, IC₅₀: 196 nM									CDK12, IC₅₀: 42 nM
CDK2-IN-9		CDK2, IC₅₀: 0.63 μM
Cdc7-IN-13																Cdc7, IC₅₀: <1 nM
CDK4/6-IN-21				CDK4, IC₅₀: 3.88 nM		CDK6, IC₅₀: 3.31 nM
CDK8-IN-17								CDK8, IC₅₀: 9 nM
Multi-target kinase-IN-7		CDK2, IC₅₀: 0.314 μM
CDK2-IN-15		CDK2, IC₅₀: 2.9 μM
P162-0948								CDK8, IC₅₀: 50.4 nM
LDC3140							CDK7, IC₅₀: <5 nM
SHR5428	CDK1, IC₅₀: >100 μM	CDK2, IC₅₀: 8.99 μM		CDK4, IC₅₀: 3.87 μM		CDK6, IC₅₀: 5.89 μM	CDK7, IC₅₀: 0.005 μM		CDK9, IC₅₀: 8.30 μM		CDK12, IC₅₀: 1.11 μM
CDK9-IN-45	CDK1, IC₅₀: 489.5 nM								CDK9, IC₅₀: 7.13 nM
VCC972839:01									CDK9, IC₅₀: 7 nM
CDK9-IN-32									CDK9
Cdc7-IN-18																Cdc7, IC₅₀: 1.29 nM
TMX-3013	CDK1, IC₅₀: 0.9 nM	CDK2, IC₅₀: <0.5 nM		CDK4, IC₅₀: 24.5 nM	CDK5, IC₅₀: 0.5 nM	CDK6, IC₅₀: 15.6 nM
CDK/HDAC-IN-2	CDK1, IC₅₀: 8.63 nM	CDK2, IC₅₀: 0.30 μM		CDK4, IC₅₀: >1000 nM		CDK6, IC₅₀: >1000 nM	CDK7, IC₅₀: >1000 nM
ZLWT-37		CDK2, IC₅₀: 0.054 μM							CDK9, IC₅₀: 0.002 μM
CDK4/6-IN-14	CDK1, IC₅₀: >10000 nM	CDK2, IC₅₀: 1045 nM		CDK4, IC₅₀: 10 nM		CDK6, IC₅₀: 16 nM	CDK7, IC₅₀: 2595 nM		CDK9, IC₅₀: 2664 nM
CLK1/4-IN-1																	CLK1, IC₅₀: 9.7 nM CLK4, IC₅₀: 6.6 nM
CDK9/PARP-IN-1									CDK9, IC₅₀: 118 nM
CDK7-IN-10							CDK7, IC₅₀: ＜100 nM
CDK2-IN-36		CDK2
CDK5-IN-2		CDK2/CycA, IC₅₀: 23 nM			Cdk5/p25, IC₅₀: 0.2 nM
CDK7-IN-6							CDK7, IC₅₀: ≤100 nM
TrkA Inhibitor	CDK1, IC₅₀: 3 μM	CDK2, IC₅₀: 0.69 μM
CDK8-IN-7								CDK8, Kd: 3.5 nM
CDK12/13-IN-3											CDK12, IC₅₀: 107.4 nM	CDK13, IC₅₀: 79.4 nM
CDK8-IN-15								CDK8, IC₅₀: 57 nM
KWZY-11						CDK6, IC₅₀: 13.3 nM
NUAK1-IN-2		CDK2		CDK4		CDK6
CDK4/6-IN-18				CDK4		CDK6
Avotaciclib sulfate	CDK1
PROTAC CDK4/6/9 degrader 2				CDK4		CDK6			CDK9
CDK2/PIM1-IN-1		CDK2, IC₅₀: 0.27 μM
PROTAC CDK9 degrader-8									CDK9, IC₅₀: 0.01 μM
CDK11A Human Pre-designed siRNA Set A																								PITSLRE
EF-4-177		CDK2/cyclinE, IC₅₀: 87 nM
Multi-kinase-IN-7		CDK2, IC₅₀: 9.31 μM			CDK5, IC₅₀: 23.4 μM
Tabersonine hydrochloride				CDK4
Cdk10 Mouse Pre-designed siRNA Set A																			CDK10
JTK-101									CDK9/cyclinT1
Cdk15 Rat Pre-designed siRNA Set A																				CDK15
Cdk20 Rat Pre-designed siRNA Set A																							CDK20
Olomoucine II	Cdk1/cyclin B, IC₅₀: 7.6 μM	CDK2/cyclinE, IC₅₀: 0.1 μM		CDK4/cyclinD1, IC₅₀: 19.8 μM			CDK7/cyclin H, IC₅₀: 0.45 μM		CDK9/cycT, IC₅₀: 0.06 μM
Cdk18 Rat Pre-designed siRNA Set A																						CDK18
2-Cyanoethylalsterpaullone	Cdk1/cyclin B, IC₅₀: 0.23 nM
CCT68127		CDK2					CDK7		CDK9
Alisol B 23-acetate (Standard)				CDK4		CDK6
CDK2-IN-27	CDK1/cyclinB1, IC₅₀: >10-20 nM nM	CDK2/cyclin E1, IC₅₀: <10 nM
CDK8-IN-16								CDK8, IC₅₀: 5.1 nM							CDK19, IC₅₀: 5.6 nM
Riviciclib	CDK1-Cyclin B, IC₅₀: 0.079 μM	cdk2-cyclin A, IC₅₀: 0.224 μM cdk2-cyclin E, IC₅₀: 2.540 μM		cdk4-cyclin D1, IC₅₀: 0.063 μM		cdk6-cyclin D3, IC₅₀: 0.396 μM			CDK9- Cyclin T1, IC₅₀: 0.020 μM CDK9-cyclin H, IC₅₀: 2.900 μM
Indirubin-3'-monoxime-5-sulphonic acid	CDK1, IC₅₀: 5 nM				CDK5, IC₅₀: 7 nM
Indirubin-5-sulfonate	Cdk1/cyclin B, IC₅₀: 55 nM	cdk2/cyclin A, IC₅₀: 35 nM CDK2/cyclinE, IC₅₀: 150 nM		Cdk4/cyclin D1, IC₅₀: 300 nM	CDK5/p35, IC₅₀: 65 nM
IIIM-290		CDK2/A, IC₅₀: 90 nM							CDK9/T1, IC₅₀: 94 nM

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

CDK Inhibitors

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z